# A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

> **NCT03981822** · PHASE2 · COMPLETED · sponsor: **Verrica Pharmaceuticals Inc.** · enrollment: 105 (actual)

## Conditions studied

- Condylomata Acuminata
- Papillomavirus Infections
- Skin Diseases, Viral
- Skin Diseases, Infectious
- Skin Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Warts

## Interventions

- **COMBINATION_PRODUCT:** VP-102 and applicator
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT03981822
- **Lead sponsor:** Verrica Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-25
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-07-08
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2024-11-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981822, "A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03981822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*